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ro the Editor: In ST-segment elevation myocardial infarction,
eperfusion with primary percutaneous coronary intervention
pPCI) is a time-sensitive process. On the basis of current
merican College of Cardiology/American Heart Association
uidelines (1), door-to-balloon time (D2B) has become a report-
ble core measure of quality and correlates with outcomes in
igh-risk and early presentation patients (2). However, reperfusion
f the infarct-related artery (IRA), measured by door-to-
eperfusion time (D2R), can occur at a time other than that of the
nitial balloon or device deployment. The purpose of our analysis
as to compare D2B and D2R to determine how often D2B
vermeasured, undermeasured, or was equivalent to D2R.
We prospectively studied 145 consecutive, nontransferred pa-
ients who presented to our emergency room with ST-segment
levation myocardial infarction and underwent pPCI between
ecember 14, 2007, and December 13, 2008. All patients received
spirin, unfractionated heparin, and eptifibatide before the proce-
ure. We recorded D2B (time from emergency room arrival to the
rst use of an intracoronary balloon, stent, or thrombectomy device
n the IRA) and D2R (time from emergency room arrival to the
rst documentation of TIMI [Thrombolysis In Myocardial Infarc-
ion] flow grade 2 or 3 in the IRA) for each patient. An
ndependent reviewer later verified D2R.
The D2B and D2R variables were significantly skewed, and the
ample size was not large enough to approximate normal Gaussian
istributions. Therefore, comparisons between D2B and D2R
ere performed using Wilcoxon matched-pairs signed rank test-
ng, reported as median values with associated ranges of the 25th
nd 75th percentiles. A 2-tailed p value 0.05 was considered
ignificant. All statistical analyses were performed using STATA
ersion 7 (Stata Corp., College Station, Texas).
In our series of 145 consecutive cases, D2B was equal to D2R
n 43 cases (30%), longer (reperfusion documented before device
tilization) in 84 cases (58%), and shorter (additional device and/or
rug therapy required after the first device to establish TIMI flow
rade 2 or 3) in 18 cases (12%) (Fig. 1). We found D2B was longer
han D2R by 5 min in 59 cases (41% of total cases), and by 10
in in 30 cases (21% of total cases). The median time for D2B to
ccur was of 67 min (25% to 75%, range 53 to 81 min) and for
2R, it was 61 min (25% to 75%, range 49 to 77 min). The
ifference between D2B and D2R (case-by-case D2B minus D2R)
as highly significant (median of 2 min, Wilcoxon rank sum
ighly significant at p  0.0001).
Our findings indicate that D2B commonly overmeasures D2R
D2B  D2R in 58% of cases), where reperfusion is documented
efore device utilization. Upon reperfusion, the patient may benefit
rom the team having “nonpenalized” time to reassess the patient’s slinical, hemodynamic, and anticoagulant status and to consider
arious strategies of therapy including balloon dilation, direct
tenting, thrombectomy, and/or adjunctive pharmacologic sup-
ort. Direct stenting, which is perhaps advantageous following
stablishment of flow (3), is better performed by pre-deployment
dministration of intracoronary vasodilators. This nonpenalized
ime spent to optimize final reperfusion stands in stark contrast to
gaming strategy of blindly plodding ahead according to
re-specified and potentially inappropriate procedural protocol
o selfishly optimize a metric (D2B). This is acknowledged by
he 2008 American College of Cardiology/American Heart
ssociation Task Force on Performance Measures, who states
hat “the goal of pPCI is to restore flow in the IRA,” and that
n cases in which reperfusion occurs before device utilization,
the operator may use more time in the consideration of the
pproach to device therapy without significant adverse conse-
uences for the patient” (4).
Our findings indicate that D2B sometimes undermeasures D2R
D2B  D2R in 12% of cases), where additional device and/or
rug therapy are required to establish reperfusion (Fig. 1). In this
ircumstance, although the metric has been “achieved” (device
tilization), the patient and purpose have not yet been served
reperfusion).
Whereas D2B reflects the quality of an institution’s process of
are, D2R more accurately reflects patient outcomes. This dicho-
omy was addressed by the 2008 Task Force, who supported the
rocess of device (D2B), as opposed to the outcome of reperfusion
D2R), citing the consistency of this metric with existing guide-
ines (1) and the more objective ascertainment of device time by
onclinical abstractors. They acknowledged, however, that D2B
oes not identify the time of reperfusion and that this is a process
easurement and not a performance measurement. Others (5),
owever, have supported tracking time to reperfusion, citing the
ore accurate correlation to clinical outcome and the unfortunate
ush toward gaming a system to benefit a device metric rather than
linical outcome.
The difference between D2B and D2R is statistically significant
nd warrants reconsideration of which metrics institutions and
rofessional societies track, compare, and report. We found that
2B is an accurate metric for the quality of an institution’s process
f care, and D2R is the better metric by which to assess the quality
f care regarding patient outcomes. We should track both D2B
nd D2R as key metrics in pPCI, hopefully allaying an unnecessary
nd inappropriate force to rush to device therapy upon initial
eperfusion, while heightening efforts to achieve reperfusion
hould it fail with initial device therapy.
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Figure 1 Frequency of Values for D2B Minus D2R (n  145)
The difference between D2B and D2R for each case. D2B  door-to-balloon time;or Sanofi-Aventis.
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Catheter Cardiovasc Interv 2008;72:424–5.Letters to the EditorIAL Trial Not Included
n a Review of Health Failure
anagement Programs
ecently, Clark et al. (1) reviewed what they considered all
vailable evidence on the effectiveness of disease management trialsethodological quality. They particularly emphasized the poor
uality of reports and design methods suggested by the Consoli-
ated Standards of Reporting Trials statement.
We fully agree with the importance of following such rules, not
nly during the reporting and writing phase but also during the
esign and implementation of clinical trials.
For this reason, we were surprised by the omission of the DIAL
Randomized Trial of Telephone Intervention in Chronic Heartlues fo
es in bi
D2R ailure) (2) from the investigators’ discussion. DIAL was the
